SOX9 and liver cancer: However, in contrast to Sox9 LKO or YAP1 alone-mediated liver cancer studies, acute Sox9 disruption using the CRISPR/Cas9 system robustly repressed Akt-YAP1 cHCC-CCA formation, irrespective of tumor fate.